Title: Mikko Airavaara: Innovator in Pharmaceutical Compositions
Introduction: Mikko Airavaara is a notable inventor based in Helsinki, Finland. He is currently associated with Herantis Pharma Plc., where he contributes to advancements in pharmaceutical research. Despite having no granted patents to his name, his work focuses on innovative solutions for treating degenerative diseases.
Latest Patent Applications: Mikko Airavaara's latest patent applications include the development of C-terminal CDNF and MANF fragments, along with pharmaceutical compositions comprising these fragments and their uses. The present invention provides a C-terminal CDNF fragment sequence or a sequence that has at least 80% homology or sequence identity to said sequence. This C-terminal CDNF fragment protects ER stressed neurons, motoneurons, and dopaminergic neurons, and is capable of penetrating neuronal cell membranes as well as the blood-brain barrier. Furthermore, the invention includes pharmaceutical compositions comprising this fragment for use in treating degenerative diseases and disorders, including central nervous system diseases, diabetes, and retinal disorders. Additionally, the invention provides a C-terminal MANF fragment sequence or a sequence with at least 80% homology or sequence identity to the said sequence, along with pharmaceutical compositions for treating similar degenerative diseases and disorders.
In another application, the present invention offers a C-terminal CDNF fragment sequence or a sequence with at least 90% homology to said sequence. This fragment also protects ER stressed neurons, motoneurons, and dopaminergic neurons, and is capable of penetrating neuronal cell membranes and the blood-brain barrier. The pharmaceutical compositions comprising this fragment are intended for use in treating degenerative diseases and disorders, including central nervous system diseases, diabetes, and retinal disorders. The invention further includes a C-terminal MANF fragment sequence or a sequence with at least 90% homology to the said sequence, along with pharmaceutical compositions for treating similar conditions.
Conclusion: Mikko Airavaara is an innovative inventor whose work in pharmaceutical compositions aims to address significant health challenges. His contributions to the field of degenerative disease treatment highlight the importance of ongoing research and development in this area.